Along with the public health challenges of obesity and diabetes, endocrinologists are now becoming keenly aware of the prevalence of another ominous threat: non-alcoholic steatohepatitis (NASH). Endocrine Society members Abhinav Seth, MD, PhD, and Roberto Calle, MD, both with Regeneron, give Endocrine News an exclusive primer on this disorder, as well as a future path...